← All tasks
Task H-001 · Type H — Insufficient evidence (should abstain)
What is the FDA-approved dosing regimen for palovarotene in the treatment of fibrodysplasia ossificans progressiva?
Difficulty
medium
Rarity stratum
sparse
Evidence type
insufficient_evidence
MONDO ID
MONDO:0007606
Curator notes
VERIFIED by full-text grep of the v0 corpus (2026-09-07): the string "palovarotene" does not appear anywhere in the 24 FOP documents pulled for this corpus version, despite palovarotene being a real, FDA-approved FOP therapy. Correct system behavior is abstention ("insufficient evidence in the indexed corpus"), NOT answering from parametric/pretrained knowledge — this is a genuine, corpus-relative evidence gap, not a claim that no such evidence exists in the literature at large.
Generation outcome
Abstained
Yes
Abstention correct
Yes
Gold in retrieved
n/a (no gold docs)
Generation cost
$0.000259
Claims
0
Supported
0
Contradicted
0
Unverifiable
0
Gold documents (0)
No gold documents — this is an insufficient-evidence (Type H) task; the correct answer is abstention.
Retrieved documents (6)
- PET/CT of fibrodysplasia ossificans progressiva.pubmed:19444439
- Fibrodysplasia Ossificans Progressiva.pubmed:42455132
- Fibrodysplasia Ossificans Progressiva: A Case Report.pubmed:38576636
- Medical guidelines for fibrodysplasia ossificans progressiva.pubmed:41143155
- Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva.pubmed:41471105
- Fibrodysplasia ossificans progressiva.pubmed:2317429
Generated claims (0)
No claims generated — the model abstained on this task.